oregoncancer.com
Apr 3, 2025, 12:42
NCCN updates guidelines, favoring DPYD testing for colon, anal, rectal, and small bowel cancers – Precision Medicine
Precision Medicine shared a post on LinkedIn:
“The National Comprehensive Cancer Network (NCCN) has updated its guidelines for colon, anal, rectal, and small bowel cancer treatment, taking a more favorable stance on DPYD pharmacogenetic testing.
What does this mean?
- Doctors are now advised to discuss DPYD testing with patients to assess their risk of severe or life-threatening toxicities from fluoropyrimidine-based chemotherapies.
- This testing can help identify patients who may require adjusted chemotherapy dosing to minimize risks.
Why is this important?
- DPYD genetic variants can affect how patients metabolize certain chemotherapies, increasing the risk of toxicities.
- By identifying these variants, healthcare providers can take steps to personalize treatment and improve patient outcomes.”
Radu Serescu, Oncologist at Amethyst Radiotherapy Romania, shared this post, adding:
“Implemented since 2021, a small percentage may exhibit toxicity to Capecitabine or 5-FU through deficient metabolism given by DPD. Testing for Amethyst! Health comes first, so I’d better inform you!”
More posts featuring Precision Medicine.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 3, 2025, 10:40
Apr 3, 2025, 10:27
Apr 3, 2025, 10:23